← Back to headlines
Alnylam Targets 25% CAGR with Innovative Therapies
Alnylam Pharmaceuticals is targeting a 25% compound annual growth rate (CAGR) through its focus on innovative therapies.
26 Mar, 07:27 — 26 Mar, 07:27
Sources
Showing 1 of 1 sources
Related Stories
Manila Water prepares for summer heat and high demand
just now
Philippines Announces Results of April 2026 Physicians Licensure Examination
just now
Pagasa flags 2 areas for dangerous heat index levels on April 9
just now
Philippines Experiences High Heat Index, DOH Issues Warnings as Areas Log Danger Levels
just now